United Therapeutics (UTHR) Reports INCREASE Study of Tyvaso Meets Primary and All Secondary Endpoints

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/7/2026

1. MU
2. APTX:CN
3. SPY
4. IQMX
5. MSTR
6. EROC
7. SEER
8. NVDA
9. RIVN
10. TSLA

Go back to United Therapeutics (UTHR) Reports INCREASE Study of Tyvaso Meets Primary and All Secondary Endpoints

United Therapeutics Announces INCREASE Study Of Tyvaso® Meets Primary And All Secondary Endpoints

February 24, 2020 6:00 AM EST

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Feb. 24, 2020 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) today announced that preliminary analysis indicates that the INCREASE clinical study of Tyvaso® (treprostinil) Inhalation Solution in patients suffering from World Health Organization (WHO) Group 3 pulmonary hypertension associated with interstitial lung disease (PH-ILD) has met its primary efficacy endpoint of demonstrating improvement in six-minute walk distance (6MWD).  

... More